Nanomix has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its eLab COVID-19 rapid antigen test, which runs on the company's eLab analyzer.
The assay can provide results in 15 minutes from a self-administered nasal swab sample, according to Nanomix. It's suitable for use in a range of settings such as hospitals, nursing homes, assisted living facilities, urgent care centers, and emergency medical care, the firm said.
